| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
1) The aim of this study was to clarify the expression profile of HDAC7 in CCC. As a result, we concluded that HDAC7 may fail to become an indicator of the clinical outcome. 2) Lately, HDAC attracts the attention as target molecule of the cancer therapy. In this theme, we assessed mRNAs expression of HDAC in variable cultured ovarian cancer cell lines. HDAC inhibitor (HDI)-induced changes in the expression of mRNAs for HDAC7, HIF-1α and VEGF were also attempted to assess the potential of HDI as anti-cancer drug. As a result, it was supposed that the response to HDI may vary greatly among the ovarian carcinomas but may be a suitable candidate for HDI treatment. 3) High frequency of polymorphic variants of HIF-1α gene (C1772T) has been reported in variable malignancies. It was carried out to demonstrate HIF-1α gene polymorphic variation in CCC, by HIF-1α sequence analysis. HIF-1α gene variation was detected in 23.6%.
|
